Cellebrite (CLBT) Q2 2026 earnings review
Sudden CEO Exit and Guidance Cut Derail the Hyper-Growth Narrative
Cellebrite delivered a shock to investors: an abrupt CEO replacement accompanied by a significant cut to its full-year ARR and Revenue guidance. The hyper-bullish narrative from just three months ago—driven by AI hype and federal rebounds—has been replaced with a sobering reality of elongated sales cycles and slower platform conversions. While the top-line story is decelerating, management impressively raised full-year Adjusted EBITDA targets, proving the business has robust operating leverage and cost control. However, the sudden break in investor trust outweighs the margin expansion.
🐂 Bull Case
Despite slashing the top-line outlook, management raised the FY26 Adjusted EBITDA target to $153M-$159M (~28% margin). The company is highly cash-generative with a 28% TTM Free Cash Flow margin.
Recurring revenue dollar-based net retention rate (NRR) ticked up to 117% from 115% in Q1, proving that the existing customer base is still successfully expanding despite broader sales cycle delays.
🐻 Bear Case
Former CEO Tom Hogan, who drove a massive re-rating of the stock based on AI enthusiasm in Q1, was suddenly replaced by Shiven Ramji, who only joined in May 2026. This signals potential execution missteps.
The company cited 'less expansion from Inseyets conversions than anticipated'—a direct contradiction to previous quarters where platform upgrades were touted as effortless and ahead of schedule.
⚖️ Verdict: 🔴
Bearish. While the EBITDA expansion is excellent, the combination of a surprise CEO departure and a slashed ARR guidance implies serious execution hiccups and breaks the momentum story that was driving the stock.
Key Themes
Sudden Leadership Change & Narrative Reversal
The transition from Tom Hogan to Shiven Ramji as CEO, effective immediately, is highly concerning given the timing. Hogan was exceptionally bullish on the Q1 call in May, predicting AI could 'double the company's revenue.' Ramji's first act was to slash the FY26 ARR outlook and take a 'measured view' of new products. This whiplash breaks management credibility.
Inseyets Conversions Are Stalling
Management explicitly cited 'less expansion from Inseyets conversions than anticipated' as a reason for the ARR miss. This directly contradicts the Q1 and Q4 narratives, which claimed the installed base conversion was tracking well ahead of schedule and acting as a massive growth vector. It appears the easy conversions are done, and the remaining base is harder to upsell.
Macro Pressures: Elongated Sales Cycles
The company noted 'longer sales cycles' impacting Q2 performance. After brushing off macro concerns in Q1, Cellebrite is now facing the reality of tighter budget scrutiny among government and enterprise clients, directly impacting their ability to close net new ARR.
AI Monetization (Genesis) Pushed Out
In Q1, Cellebrite Genesis (agentic AI) was hyped as having a $12.5B TAM with early monetization slated for Q2. While they achieved 'early monetization,' the new CEO stated they are taking a 'more measured view of that contribution in the near term' due to cycle timing. The immediate financial impact of AI has been vastly walked back.
Accelerating Operating Leverage
Despite the top-line guidance cut, operating discipline is shining through. The company raised its FY26 Adjusted EBITDA target to $153M-$159M (an implied ~28% margin). Q2 margins hit 24.2%, and Q3 is guided to accelerate further to 29-30%.
FedRAMP High Authorization Yielding Results
Cellebrite signed its first significant FedRAMP deal for Guardian (SaaS-based evidence management) via the Cellebrite Government Cloud. This validates the massive 18+ month investment to achieve DOJ-sponsored FedRAMP High status, unlocking deep pools of US Federal cloud budgets.
International Markets Provide Stability
While US execution faced hurdles, the company reported 'healthy second-quarter growth in Asia-Pacific and EMEA.' This continues the trend of D&I (Defense & Intelligence) budgets globally supporting the baseline recurring revenue.
Other KPIs
FCF margin stands at a highly robust 28.0%. While slightly down from the 32% TTM margin reported in Q1, it highlights that Cellebrite's underlying cash generation engine remains fully intact, providing a safe floor for the business while they navigate GTM transition issues.
There is a massive spread between GAAP ($0.02 EPS) and Non-GAAP ($0.11 EPS) earnings. The $23.3M difference is driven heavily by $15.2M in share-based compensation and $6.9M in amortization of intangibles. Investors must monitor stock dilution given the heavy reliance on SBC.
Guidance
Decelerating. Lowered from the previous range of $567M-$573M. The new midpoint implies 15% YoY growth, down heavily from the 21% growth achieved in Q1 and Q2. This implies a sharp slowdown in net new ARR additions in the second half of the year.
Decelerating. Lowered from the previous range of $565M-$571M. Implies 17-18% annual growth.
Accelerating. Raised from the previous range of $149M-$155M. Implies an annual margin of ~28%. This highlights successful cost containment measures executed in the wake of slower-than-expected top-line velocity.
Decelerating. Represents 19-20% YoY growth. Because Q3 is guided at ~19.5% growth and the full year is guided at 15% growth, the implied Q4 ARR growth rate drops significantly, pointing to a very weak expected finish to the year compared to historical seasonality.
Decelerating. Represents 15-17% annual growth, a sequential step down in growth rates.
Accelerating. Implies a highly profitable 29-30% margin, up substantially from the 24.2% delivered in Q2.
Key Questions
Inseyets Sales Cycle Bottlenecks
You specifically called out less expansion from Inseyets conversions. What exactly is stalling these upgrades? Is it a budget issue, a technical migration hurdle, or pushback on pricing?
CEO Transition Dynamics
Tom Hogan expressed massive enthusiasm for the multi-year vision just 90 days ago. Was his departure performance-related tied to the Q2 ARR miss, or were there strategic disagreements on the pacing of AI investments?
Q4 Implied ARR Cliff
Your Q3 ARR guidance implies roughly 19.5% YoY growth, yet your full-year guide is 14-16%. This mathematically implies a dramatic drop in Q4 ARR growth. Are you seeing specific Q4 deal risks, or is this just extreme conservatism under the new CEO?